BREAKING NEWS: Apotex appeals Preliminary Injunction Order to Federal Circuit

Amgen v. Apotex (pegfilgrastim)  •  Biosimilar News  •  BPCIA and Related U.S. Statutes

As we covered yesterday, the district court issued an order in Amgen v. Apotex granting Amgen a preliminary injunction that would prohibit Apotex from launching its biosimilar pegfilgrastim product until 180 days after it receives FDA approval and gives notice of commercial marketing. Today, Apotex filed a notice of appeal of that order to the Federal Circuit. The notice of appeal is available here.

Stay tuned for further updates and analysis.

Download PDF

Tagged with 

Comments are closed.